169 related articles for article (PubMed ID: 34181339)
1. CCA-1.1, a Novel Curcumin Analog, Exerts Cytotoxic anti- Migratory Activity toward TNBC and HER2-Enriched Breast Cancer Cells.
Novitasari D; Jenie RI; Utomo RY; Kato JY; Meiyanto E
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1827-1836. PubMed ID: 34181339
[TBL] [Abstract][Full Text] [Related]
2. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation.
Meiyanto E; Putri DD; Susidarti RA; Murwanti R; Sardjiman ; Fitriasari A; Husnaa U; Purnomo H; Kawaichi M
Asian Pac J Cancer Prev; 2014; 15(1):179-84. PubMed ID: 24528023
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and Antimetastatic Activity of Hesperetin and Doxorubicin Combination Toward Her2 Expressing Breast Cancer Cells.
Nurhayati IP; Khumaira A; Ilmawati GPN; Meiyanto E; Hermawan A
Asian Pac J Cancer Prev; 2020 May; 21(5):1259-1267. PubMed ID: 32458631
[TBL] [Abstract][Full Text] [Related]
4. The Growth Suppression Activity of Diosmin and PGV-1 Co-Treatment on 4T1 Breast Cancer Targets Mitotic Regulatory Proteins.
Musyayyadah H; Wulandari F; Nangimi AF; Anggraeni AD; Ikawati M; Meiyanto E
Asian Pac J Cancer Prev; 2021 Sep; 22(9):2929-2938. PubMed ID: 34582664
[TBL] [Abstract][Full Text] [Related]
5. The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells.
Meiyanto E; Husnaa U; Kastian RF; Putri H; Larasati YA; Khumaira A; Pamungkas DDP; Jenie RI; Kawaichi M; Lestari B; Yokoyama T; Kato JY
Adv Pharm Bull; 2021 Jan; 11(1):188-196. PubMed ID: 33747866
[No Abstract] [Full Text] [Related]
6. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE
Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049
[TBL] [Abstract][Full Text] [Related]
7. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
Ünal TD; Hamurcu Z; Delibaşı N; Çınar V; Güler A; Gökçe S; Nurdinov N; Ozpolat B
Anticancer Agents Med Chem; 2021; 21(3):355-364. PubMed ID: 32767958
[TBL] [Abstract][Full Text] [Related]
8. Reverse engineering of triple-negative breast cancer cells for targeted treatment.
Bluemel L; von Wahlde MK; Tio J; Kiesel L; Bernemann C
Maturitas; 2018 Feb; 108():24-30. PubMed ID: 29290211
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
Kundur S; Prayag A; Selvakumar P; Nguyen H; McKee L; Cruz C; Srinivasan A; Shoyele S; Lakshmikuttyamma A
J Cell Physiol; 2019 Jul; 234(7):11103-11118. PubMed ID: 30478904
[TBL] [Abstract][Full Text] [Related]
10. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
11. Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells.
Baghi N; Bakhshinejad B; Keshavarz R; Babashah S; Sadeghizadeh M
Gene; 2018 Sep; 670():55-62. PubMed ID: 29753810
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5.
Kamalabadi-Farahani M; H Najafabadi MR; Jabbarpour Z
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1743-1748. PubMed ID: 31244295
[TBL] [Abstract][Full Text] [Related]
13. Combination of Potassium Pentagamavunon-0 and Doxorubicin Induces Apoptosis and Cell Cycle Arrest and Inhibits Metastasis in Breast Cancer Cells.
Putri H; Jenie RI; Handayani S; Kastian RF; Meiyanto E
Asian Pac J Cancer Prev; 2016; 17(5):2683-8. PubMed ID: 27268651
[TBL] [Abstract][Full Text] [Related]
14. The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells.
Jenie RI; Utomo RY; Susidarti RA; Novitasari D; Kirihata M; Meiyanto E
Asian Pac J Cancer Prev; 2021 Jan; 22(1):151-155. PubMed ID: 33507693
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
16. H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells.
Pandolfi L; Bellini M; Vanna R; Morasso C; Zago A; Carcano S; Avvakumova S; Bertolini JA; Rizzuto MA; Colombo M; Prosperi D
Biomacromolecules; 2017 Oct; 18(10):3318-3330. PubMed ID: 28886247
[TBL] [Abstract][Full Text] [Related]
17. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.
Brouxhon SM; Kyrkanides S; Teng X; O'Banion MK; Clarke R; Byers S; Ma L
Mol Carcinog; 2014 Nov; 53(11):893-906. PubMed ID: 23776059
[TBL] [Abstract][Full Text] [Related]
18. In vitro synergistic effect of hesperidin and doxorubicin downregulates epithelial-mesenchymal transition in highly metastatic breast cancer cells.
Amalina ND; Salsabila IA; Zulfin UM; Jenie RI; Meiyanto E
J Egypt Natl Canc Inst; 2023 Mar; 35(1):6. PubMed ID: 36967442
[TBL] [Abstract][Full Text] [Related]
19. The Cytotoxic and Anti-Migratory Properties of Caesalpinia sappan and Ficus septica, in Combination with Doxorubicin on 4T1 TNBC Cells with Nephroprotective Potential.
Haryanti S; Zulfin UM; Salsabila IA; Wulandari F; Meiyanto E
Asian Pac J Cancer Prev; 2022 Feb; 23(2):743-752. PubMed ID: 35225488
[TBL] [Abstract][Full Text] [Related]
20. Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells.
Thulasiraman P; McAndrews DJ; Mohiudddin IQ
BMC Cancer; 2014 Sep; 14():724. PubMed ID: 25260874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
